98%
921
2 minutes
20
Introduction: Ultrasound-guided thrombin injection (UGTI) is the preferred treatment of pseudoaneurysms (psA). The potential risk of complications increases with the number of UGTI treatments needed for complete psA obliteration. Identification of risk factors for recurrent psA is needed.
Material And Methods: In total, 508 patients with femoral artery psA underwent UGTI, followed by ultrasound examination repeated twice, at 1-week intervals, to assess UGTI effectiveness. In cases of psA recurrence, the procedure was repeated. Clinical and ultrasound data were prospectively collected.
Results: The psA recurrence occurred in 76 (15%) patients. UGTI was repeated twice in 49 (64%), three times in 15 (20%) and more than three times in 12 (16%) patients. The median thrombin dose was 150 IU (80-250 IU), and was lower in initial procedures than repeated UGTI ( = 0.025). The median psA volume was 2.26 ml (0.86-5.47 ml). The median length of the communicating channel was 4 mm (0-12 mm). A time interval between vessel catheterization and UGTI greater than 7 days ( < 0.001), a late to early velocity index (LEVI) of < 0.2 identified during the outflow phase ( < 0.001), a psA volume > 5 ml ( = 0.032), and a short communicating channel between the psA and the artery ( = 0.037) predicted psA recurrence. Antiplatelet and anticoagulant agents did not increase the risk.
Conclusions: The LEVI and time interval between artery cannulation and UGTI treatment are strong parameters identifying patients at risk of psA recurrence. The psA volume and communicating channel length are less substantial risks, but still significant. Concomitant antiplatelet and anticoagulant therapy do not affect the success rate of UGTI.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130474 | PMC |
http://dx.doi.org/10.5114/aoms.2019.85249 | DOI Listing |
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
Introduction: The introduction of novel robotic platforms has expanded surgical options for robot-assisted radical prostatectomy (RARP). However, comparative outcomes with da Vinci multiport (MP) system remain unclear. This systematic review and network meta-analysis aimed to compare perioperative, early oncological, and functional outcomes of RARP performed with novel robotic platforms versus the da Vinci MP system.
View Article and Find Full Text PDFUrol Oncol
September 2025
Faculty of Medicine, Department of Nuclear Medicine, Gazi University, Beşevler Ankara, Turkey.
Background: This study aimed to evaluate the diagnostic performance of Ga-PSMA-11 PET/MRI in prostate cancer (PC) with biochemical recurrence (BCR) after radical prostatectomy (RP). It was also aimed to develop a nomogram to predict PET/MRI positivity.
Methods: The data of 140 PC patients who underwent Ga-PSMA-11 PET/MRI for BCR after RP were retrospectively analyzed.
Can J Urol
August 2025
Department of Urology, Duke University Hospital, Durham, NC 27710, USA.
Background: Radical prostatectomy has long been the treatment of choice for men with clinically significant prostate cancer (PCa) in those with concurrent significant lower urinary tract symptoms (LUTS). For men who meet this description with marked prostatomegaly, we present a multi-institutional proof of concept study describing an alternative pathway of robotic simple prostatectomy (RASP) followed by external beam radiation therapy (EBRT) for the treatment of clinically significant prostate cancer.
Methods: A retrospective study was performed of 17 patients with PCa who underwent RASP followed by EBRT at two institutions from 2015-2023.
IJU Case Rep
September 2025
Department of Urology, Faculty of Medicine, Saga University, Saga, Japan.
Introduction: We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.
Case Presentation: A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL.
Purpose: Perineural invasion (PNI) and lymphovascular invasion (LVI) represent tumor escape mechanisms at radical prostatectomy (RP). We assessed their prognostic significance for biochemical recurrence (BCR) following complete resection.
Methods: We analyzed 10,471 men with negative surgical margins after RP, stratified into three groups based on pathological PNI and LVI status: Group 1 (PNI-/LVI-, n = 1,925), Group 2 (PNI+/LVI-, n = 7,849), and Group 3 (LVI+, n = 697; 14 with PNI-/LVI + and 683 with PNI+/LVI+).